[Cancer Management and Research] The research examines the various combination strategies for the treatment of multiple myeloma, with a focus on the use of elotuzumab.
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.
Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.
Men who had PSA progression on enzalutamide but continued on the drug did not have improved PFS when abiraterone was added to their therapy.
Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.
Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.
New paradigm of hormone therapy, surgery, and radiation therapy was shown effective at achieving undetectable disease in patients with metastatic prostate cancer.
Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.
Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian CancerApril 20, 2017
Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.
The combination of an anticancer agent with a rheumatoid arthritis medication results in synergistic effect that improves the efficacy of the anticancer agent.
Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.
The addition of temozolomide to short-course radiotherapy in elderly patients with glioblastoma was associated with some survival benefit compared with radiotherapy alone.
A new approach in which patients receive a single dose of chemotherapy may greatly improve the laryngeal cancer survival rate.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaFebruary 15, 2017
In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.
Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
Study investigates the effectiveness of a topical treatment with an immune system-activator and a topical chemotherapy on actinic keratosis, a precursor to squamous cell carcinoma.
The combination of bendamustine, lenalidomide, and dexamethasone was highly active as second-line treatment for relapsed/refractory multiple myeloma.
In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.
In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.
The US FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of certain patients with soft tissue sarcoma.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.
Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.
Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple MyelomaAugust 16, 2016
The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).
Chemoradiation Combination Could Preserve Larynx in Patients With Laryngeal and Hypolaryngeal CancerAugust 04, 2016
Researchers assessed the rates of laryngeal preservation and laryngectomy-free survival in patients with laryngeal or hypopharyngeal cancer who received the monoclonal antibody cetuximab and radiation therapy or radiation therapy alone.
Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).
Resistance to therapy through adaptation poses a major hurdle for cancer therapy. Bioengineers addressed this by creating a single nanoparticle that comprises a synergistic drug pair that shuts down mechanisms of resistance to a degree that has not been previously achieved.
- Optimal Treatment Regimens for Oldest Patients Is an Emerging Challenge for Radiation Oncology
- Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab
- Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Bullying Common to Nursing Students
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Risk of Arterial Thromboembolism Greater With First-Time Cancer
- Digital Recording in Skills Lab Beneficial for Nursing Students
- Colorectal Cancer Recurrence Lower in Survivors Who Exercise
- Cancer Patient Caregivers Have Increased Burden With Assessment Dissonance
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|